Search Results - "Atopic dermatitis"

Blackstone Injects Up to $1.3 Billion Into Apogee Skin Drug.

Authors: Smith, Gerry (AUTHOR)

Source: Bloomberg.com. 5/27/2026, pN.PAG-N.PAG. 1p.

Blackstone Injecting Up to $1.3 Billion in Apogee for Skin Drug.

Authors: Smith, Gerry (AUTHOR)

Source: Bloomberg.com. 5/27/2026, pN.PAG-N.PAG. 1p.

Management of Moderate‐to‐Severe Atopic Dermatitis With Systemic Medications: Review and Expert Commentary.

Authors: Adam, David N. Dhadwal, Gurbir Grewal, Parbeer et al.

Source: Dermatologic Therapy. 6/19/2026, Vol. 2026, p1-17. 17p.

Cannabidiol Alleviates Symptoms of Senile Atopic Dermatitis by Inhibiting Fibroblast Senescence.

Authors: Jin, Mei-Tong Zhang, Wen-Lian Guan, Jing-Yuan et al.

Source: Dermatologic Therapy. 6/16/2026, Vol. 2026, p1-11. 11p.

A Durability Index for Atopic Dermatitis: Indirect Comparison of Lebrikizumab, Dupilumab, and Tralokinumab in Maintaining Efficacy Under Variable Treatment Adherence.

Authors: Silverberg, Jonathan I. Irvine, Alan D. Foley, Peter et al.

Source: Dermatology & Therapy. Jun2026, p1-20. 20p.

Pruritogenic mediators in atopic dermatitis: mechanisms of neurogenic crosstalk.

Authors: Wong, Lai-San Yang, Jen-Hau Yen, Yu-Ta et al.

Source: Journal of Cutaneous Immunology & Allergy. 2026, p1-9. 9p.

Beyond the Skin: Assessing Itch in Atopic Dermatitis – Insights from UK Dermatologists. A Cross-Sectional Survey and Narrative Review.

Authors: Laws, Philip Barea, Alberto Fremlin, Georgina et al.

Source: Dermatology & Therapy. Jun2026, Vol. 16 Issue 6, p2689-2703. 15p.

Summary of Research: Immunogenicity of Dupilumab in Adult and Pediatric Patients with Atopic Dermatitis.

Authors: Kosloski, Matthew P. Lai, Ching-Ha Partridge, Michael A. et al.

Source: Dermatology & Therapy. Jun2026, Vol. 16 Issue 6, p2603-2606. 4p.

Patients with Atopic Dermatitis and Insufficient Response to Conventional Systemic Therapy in Germany: A Health Claims Data Analysis.

Authors: Schwedhelm, Carolina Kunk, Leonie Pawlowska-Phelan, Dorota et al.

Source: Dermatology & Therapy. Jun2026, Vol. 16 Issue 6, p2905-2917. 13p.

Efficacy and Safety of the PD-1 Agonist JNJ-67484703 in Participants with Atopic Dermatitis: Phase 2a, Randomized, Double-Blind, Placebo-Controlled Trial Results.

Authors: Cecchini, Michael Kwiek, Bartlomiej Liu-Walsh, Fang et al.

Source: Dermatology & Therapy. Jun2026, Vol. 16 Issue 6, p2965-2978. 14p.

Real-World Use of Baricitinib in Patients with Atopic Dermatitis in Spain: DAMA-S Study, A Retrospective Chart Review.

Authors: Gómez de la Fuente, Enrique Herrera, Enrique Martinez-Espronceda Esquerdo, Iñigo et al.

Source: Dermatology & Therapy. Jun2026, Vol. 16 Issue 6, p2979-2996. 18p.

Sociodemographic Disparities in Atopic Dermatitis Prevalence in Spain.

Authors: Cayuela, Lucía Bueno-Molina, Rocío C. Hernández-Rodríguez, Juan-Carlos et al.

Source: Journal of Clinical Medicine. Jun2026, Vol. 15 Issue 11, p4289. 14p.

Efficacy and Safety of Lebrikizumab in the Treatment of Atopic Dermatitis: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials.

Authors: Batool, Asia Abbas, Muhammad Sharjeel Khan, Saifullah et al.

Source: Dermatologic Therapy. 5/30/2026, Vol. 2026, p1-13. 13p.

Efficacy and Safety of Variable-Dose Versus Continuous-Dose Abrocitinib Treatment in Patients with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis.

Authors: Silverberg, Jonathan I. Simpson, Eric L. Farooqui, Saleem A. et al.

Source: Dermatology & Therapy. May2026, p1-17. 17p.

The Intersection of Inflammatory Skin Diseases and Women's Reproductive Health: Challenges in Managing Psoriasis and Atopic Dermatitis During Pregnancy and Hormonal Fluctuations.

Authors: Qin, Guifang Xu, Xue Meng, Zudong et al.

Source: Dermatologic Therapy. 5/16/2026, Vol. 2026, p1-11. 11p.

Advances in Atopic Dermatitis Management: The Role of Lebrikizumab.

Authors: Mushtaq, Saba Shuja, Hafsa Ibrahim, Hamza Yousuf et al.

Source: Dermatologic Therapy. 5/14/2026, Vol. 2026, p1-15. 15p.

Efficacy and Safety of Dupilumab in Children Aged 6 months–11 years Old With Atopic Dermatitis: A Systematic Review and Meta‐Analysis.

Authors: Wei, Hua Wu, Yu Lu, Yun et al.

Source: Dermatologic Therapy. 5/16/2026, Vol. 2026, p1-9. 9p.

Real-World Effectiveness and Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A 52-Week Retrospective Italian Study Focusing on Head and Neck Involvement.

Authors: Gargiulo, Luigi Ibba, Luciano Bianco, Matteo et al.

Source: Dermatology & Therapy. May2026, Vol. 16 Issue 5, p2499-2512. 14p.

Gestational Diabetes Mellitus Increases the Risk of Atopic Dermatitis in Children: A National Retrospective Study with Analysis by Treatment Modality.

Authors: Weissmann, Sarah Amitai, Nir Honig, Eliya et al.

Source: Dermatology & Therapy. May2026, Vol. 16 Issue 5, p2513-2524. 12p.

Understanding Clinical Inertia in Atopic Dermatitis: A Mixed-Methods Study of Barriers to Treatment Escalation.

Authors: Hindelang, Michael Klimova, Daria Domenech, Arnau et al.

Source: Dermatology & Therapy. May2026, Vol. 16 Issue 5, p2411-2431. 21p.